| Cash Flow | 2025-09-30 |
|---|---|
| Net income | 1,723 |
| Depreciation and amortization | 632 |
| Deferred income tax expense (benefit) | 51 |
| Stock-based compensation expense | 79 |
| Impairment and restructuring charges, and acquisition-related costs | 66 |
| Litigation and investigation costs | -34 |
| Net gains on sales, consolidation and deconsolidation of facilities | 4 |
| Loss from early extinguishment of debt | 0 |
| Equity in earnings of unconsolidated affiliates, net of distributions received | 13 |
| Amortization of debt discount and debt issuance costs | 18 |
| Net gains from the sale of investments and long-lived assets | 2 |
| Other items, net | 3 |
| Accounts receivable | -68 |
| Inventories and other current assets | 58 |
| Income taxes | -15 |
| Accounts payable, accrued expenses and other current liabilities | 237 |
| Other long-term liabilities | 50 |
| Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements | 84 |
| Net cash provided by operating activities | 2,809 |
| Purchases of property and equipment | 646 |
| Purchases of businesses or joint venture interests, net of cash acquired | 266 |
| Proceeds from sales of facilities and other assets | 18 |
| Proceeds from sales of marketable securities and long-term investments | 74 |
| Purchases of marketable securities and long-term investments | 69 |
| Other items, net | -3 |
| Net cash provided by (used in) investing activities | -886 |
| Repayments of borrowings | 90 |
| Proceeds from borrowings | 21 |
| Repurchases of common stock | 1,188 |
| Distributions paid to noncontrolling interests | 585 |
| Proceeds from the sale of noncontrolling interests | 27 |
| Purchases of noncontrolling interests | 88 |
| Advances from managed care payers | 0 |
| Repayments of advances from managed care payers | 33 |
| Taxes paid related to net share settlement, net of proceeds from shares issued under stock-based compensation plans | 47 |
| Other items, net | 16 |
| Net cash used in financing activities | -1,967 |
| Net increase (decrease) in cash and cash equivalents | -44 |
| Cash and cash equivalents at beginning of period | 3,019 |
| Cash and cash equivalents at end of period | 2,975 |
TENET HEALTHCARE CORP (THC)
TENET HEALTHCARE CORP (THC)